AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee



Status:Completed
Conditions:Arthritis, Arthritis, Arthritis, Osteoarthritis (OA)
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:40 - 85
Updated:12/23/2017
Start Date:June 19, 2017
End Date:December 7, 2017

Use our guide to learn which trials are right for you!

A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee

This is a phase 3 randomized study is to confirm the efficacy of an intra-articular injection
of Ampion™ in adults with pain due to severe osteoarthritis of the knee.

There will be a 7-day screening period for each subject followed by a 12-week participation
period.

The primary trial objective is to evaluate the clinical efficacy of Ampion using the
OMERACT-OARSI (using the WOMAC 3.1 Index and PGA as assessments).

The secondary trial objectives are to evaluate the safety of a single intra-articular
injection (4 mL) of Ampion.


Inclusion Criteria:

- Able to provide written informed consent to participate in the study;

- Willing and able to comply with all study requirements and instructions of the site
study staff;

- Must be ambulatory;

- Study knee must have a clinical diagnosis of osteoarthritis (OA) supported by
radiological evidence (Kellgren Lawrence Grade 4) which is assessed locally (x-rays
within the past 6 months of screening are acceptable);

- Moderate to moderately-severe OA pain in the study knee (rating of at least 1.5 on the
WOMAC A, 5-point Likert Pain Subscale);

- Moderate to moderately-severe OA function in the study knee (rating of at least 1.5 on
the WOMAC C, 5-point Likert Function Subscale);

- WOMAC A, 5-point Likert pain subscale <1.5 in the contralateral knee;

- Ability to discontinue non-steroidal anti-inflammatory drug (NSAID) use at Screening
visit and/or 72 hours prior to the Baseline visit and for the duration of the clinical
study (low-dose aspirin (81 mg) is allowed during the study);

- No analgesia (including acetaminophen) taken 24 hours prior to an efficacy measure;

- No known clinically significant liver abnormality (e.g. cirrhosis, transplant, etc.).

Exclusion Criteria:

- As a result of medical review and screening investigation, the Principal Investigator
considers the subject unfit for the study

- A history of allergic reactions to human albumin (reaction to non-human albumin such
as egg albumin is not an exclusion criterion)

- A history of allergic reactions to excipients in 5% human albumin (N-acetyltryptophan,
sodium caprylate)

- Presence of tense effusions

- Inflammatory or crystal arthropathies, acute fractures, history of aseptic necrosis or
joint replacement in the affected knee, as assessed locally by the Principal
Investigator

- Isolated patella femoral syndrome, also known as chondromalacia

- Any other disease or condition interfering with the free use and evaluation of the
study knee for the duration of the trial (e.g. cancer, congenital defects, spine
osteoarthritis)

- Major injury to the study knee within the 12 months prior to screening

- Severe hip osteoarthritis ipsilateral to the study knee

- Any pain that could interfere with the assessment of study knee pain (e.g. pain in any
other part of the lower extremities, pain radiating to the knee)

- Any pharmacological or non-pharmacological treatment targeting OA started or changed
during the 4 weeks prior to randomization or likely to be changed during the duration
of the study

- Pregnancy or planning to become pregnant during the study

- Use of the following medications:

1. No intra-articular (IA) injected medications in the study knee during the study
(or 12 weeks prior to Baseline).

2. No analgesics containing opioids.

3. NSAIDs are not permitted during the study; acetaminophen is available as a rescue
medication during the study from the provided supply.

4. No topical treatment on the study knee during the study

5. No significant anticoagulant therapy (e.g. Heparin or Lovenox) during the study
(treatment such as low-dose Aspirin (81 mg) and Plavix are allowed)

6. No systemic treatments that may interfere with safety or efficacy assessments
during the study

7. No immunosuppressants

8. No use of systemic or intra-articular corticosteroids

- No human albumin treatment in the 3 months before randomization or throughout the
duration of the study
We found this trial at
13
sites
Encinitas, California 92024
Phone: 760-943-6710
?
mi
from
Encinitas, CA
Click here to add this to my saved trials
400 Tower Rd Ne
Marietta, Georgia 30060
678-581-5252
?
mi
from
Marietta, GA
Click here to add this to my saved trials
1709 S Rock Rd
Wichita, Kansas 67207
316-689-6629
?
mi
from
Wichita, KS
Click here to add this to my saved trials
Austin, Texas 78745
Phone: 512-961-3880
?
mi
from
Austin, TX
Click here to add this to my saved trials
Bellevue, Washington 98007
Phone: 425-453-0404
?
mi
from
Bellevue, WA
Click here to add this to my saved trials
Birmingham, Alabama 35205
Phone: 205-327-1077
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
13000 Maple Avenue
Blue Island, Illinois 60406
Phone: 708-388-2245
?
mi
from
Blue Island, IL
Click here to add this to my saved trials
Frederick, Maryland 21702
Phone: 301-624-1164
?
mi
from
Frederick, MD
Click here to add this to my saved trials
2720 North Harbor Boulevard
Fullerton, California 92835
Phone: 714-922-3000
?
mi
from
Fullerton, CA
Click here to add this to my saved trials
637 Dunn Road
Hazelwood, Missouri 63042
Phone: 314-972-9600
?
mi
from
Hazelwood, MO
Click here to add this to my saved trials
2880 Tricom Street
North Charleston, South Carolina 29406
Phone: 843-856-3784
?
mi
from
North Charleston, SC
Click here to add this to my saved trials
San Diego, California 92123
Phone: 858-278-3647
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Thousand Oaks, California 91360
Phone: 805-496-3322
?
mi
from
Thousand Oaks, CA
Click here to add this to my saved trials